Content about Thyroid disease

January 11, 2012

Fleming Pharmaceuticals has sold rights of several of its products to Valeant International, Fleming said Wednesday.

ST. LOUIS — Fleming Pharmaceuticals has sold rights of several of its products to Valeant International, Fleming said Wednesday.

Fleming announced the sale of the OTC nasal spray Ocean, the prescription kidney dialysis vitamin supplement Nephrocaps, the magnesium supplement Magonate and ProBarimin QT, a medical food product for patients who have received weight loss surgery. Financial terms were not disclosed.

September 27, 2011

Mass merchandiser Sam's Club is offering a free women's health screening in recognition of Breast Cancer Awareness Month, the chain said Tuesday.

BENTONVILLE, Ark. — Mass merchandiser Sam's Club is offering a free women's health screening in recognition of Breast Cancer Awareness Month, the chain said Tuesday.

July 5, 2011

APP Pharmaceuticals has received regulatory approval for the treatment of a complication related to hypothyroidism.

SCHAUMBURG, Ill. — APP Pharmaceuticals has received regulatory approval for the treatment of a complication related to hypothyroidism.

APP said that its levothyroxine sodium for injection will be marketed in single-dose 100-mcg, 200-mcg and 500-mcg vials. The drug is designed to treat myxedema coma, a life-threatening complication of hypothyroidism.

April 25, 2011

Anglo-Swedish drug maker AstraZeneca has made the drug vandetanib available to certain thyroid cancer patients.

WILMINGTON, Del. — Anglo-Swedish drug maker AstraZeneca has made the drug vandetanib available to certain thyroid cancer patients.

The drug maker announced Monday that the drug would be available to patients with medullary thyroid cancer that could not be removed surgically or that had spread to other parts of the body. The Food and Drug Administration approved the drug on April 6, and it is available exclusively through the pharmacy business unit of Biologics Inc., an integrated cancer management company.

September 22, 2010

The Food and Drug Administration has accepted AstraZeneca’s regulatory application for an investigational cancer drug,...

LONDON The Food and Drug Administration has accepted AstraZeneca’s regulatory application for an investigational cancer drug, the Anglo-Swedish drug maker said Thursday.

 

AstraZeneca announced the FDA’s acceptance of its application for vandetanib, a drug for treating patients with advanced medullary thyroid cancer. The agency gave the drug priority review status and expected to take action on it in January.